Aiforia Technologies Oyj Strengthens Financial Position with New Share Issue

Aiforia Technologies Oyj recently completed a directed share issue, raising €6.4 million through the sale of 3.6 million shares at €1.772 each. This transaction increased the total share count to 37.39 million, resulting in approximately 9.6% dilution. The funds are intended to support Aiforia's operations through Q3 2027.

Key shareholders, including TJT Technologies Oy and Mikko Laakkonen, significantly contributed to the investment. The company also holds a non-binding term sheet with the European Investment Bank, which could provide up to €20 million in venture debt. This financial strategy reduces risk and aligns with Aiforia’s goal of financial independence by the end of 2027.

The recent capital raise positions Aiforia favorably, with potential investors now focusing on business growth and revenue expansion. The company's focus on AI-powered pathology in oncology diagnostics continues to attract industry interest. Upcoming H1 financial results, expected on August 28th, are anticipated to demonstrate significant growth, particularly in the clinical segment.